Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.63 |
| ▸ | HTR3A | P46098 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914679 | 0.82 | CHRNA7 (0.74) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL30793887 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL30793442 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL30793073 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2911279 | 0.79 | CHRNA7 (0.78) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL7559030 | 0.78 | CHRNA7 (1.00) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL30251765 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5517077 | 0.77 | HTR2C (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5517082 | 0.77 | HTR2C (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL10053573 | 0.77 | HTR2C (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | CHRNA7, CHRNA5, CHRNA10 | CHRNA7 1/4885HTR3A 98/4885SMN1; SMN2 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.